PTC Therapeutics Inc PIVOT-HD Interim Data Update Call Transcript
Good day, and welcome to the PIVOT-HD interim data update call. (Operator Instructions) As a reminder, this call is being recorded.
I would now like to turn the call over to CEO, Dr. Matthew Klein. You may begin.
Thank you for joining this morning's call. We are excited to share the encouraging data from the 12-week interim analysis of the PIVOT-HD study.
Before I begin, I refer you to our forward-looking statements on this slide, which are also posted on our website as well as our Risk Factors section in our most recent 10-K.
The PTC518 Huntington's disease program comes from PTC's validated splicing classes. PTC pioneered the field of small molecule splicing And over the past 2 decades, -- we have built a robust platform to enable the identification of disease-relevant splicing targets and molecular scaffolds capable of favorably affecting splicing activity. In addition to our platform tools, we also have an outstanding team of scientists who have been leading our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |